Press Releases
Filter By Year
June
-
June 20, 2024
Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention -
June 14, 2024
New Kite Clinical Research and Real-World Evidence for Yescarta® Demonstrate Benefit From Earlier Lines of Treatment -
June 06, 2024
Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA -
June 05, 2024
Gilead’s Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis -
June 04, 2024
MEDIA UPDATE: Gilead Sciences Advances Enrollment in Collaborative Studies to Assess Twice-Yearly HIV Prevention Option for Both Cisgender Women in the U.S. and People Who Inject Drugs in the U.S. -
June 03, 2024
Kite’s Tecartus® Demonstrates Sustained Overall Survival in Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia -
June 03, 2024
Encouraging New Data Presented on Kite’s Yescarta® for Relapsed/Refractory Central Nervous System Lymphoma -
June 02, 2024
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer -
June 01, 2024
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers
May
-
May 31, 2024
EVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024 -
May 30, 2024
Gilead Provides Update on Phase 3 TROPiCS-04 Study -
May 22, 2024
Gilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024 -
May 18, 2024
Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis -
May 14, 2024
Kite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell Therapy -
May 09, 2024
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program -
May 07, 2024
Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024
April
-
April 30, 2024
Gilead Sciences to Present at Upcoming Investor Conferences -
April 26, 2024
FDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV -
April 25, 2024
Gilead Sciences Announces First Quarter 2024 Financial Results -
April 08, 2024
Gilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024
March
-
March 28, 2024
FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six -
March 28, 2024
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program -
March 22, 2024
Gilead Sciences Announces Completion of Acquisition of CymaBay -
March 11, 2024
Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender Offer -
March 06, 2024
Biktarvy® Demonstrates High Rates of Viral Suppression in People With HIV and Comorbidities -
March 06, 2024
Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24 -
March 06, 2024
Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers -
March 05, 2024
New Real-World Data Further Support the Use of Veklury® (Remdesivir) for People Hospitalized With COVID-19 -
March 05, 2024
Gilead’s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health
February
-
February 27, 2024
Gilead Announces Funding Initiative to Support HIV Prevention, Anti-Stigma and Health Equity Efforts for Black Cisgender and Transgender Women and Girls in the U.S. -
February 26, 2024
U.S. FDA Approves Expanded Indication for Gilead’s Biktarvy® to Treat People with HIV with Suppressed Viral Loads, Pre-existing Resistance -
February 26, 2024
Gilead to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline at CROI 2024 -
February 20, 2024
Gilead Sciences to Present at Upcoming Investor Conferences -
February 12, 2024
Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics -
February 09, 2024
Gilead Named One of America’s Most JUST Companies by JUST Capital and CNBC -
February 06, 2024
Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2024 Dividend -
February 06, 2024
Gilead Sciences Announces Fourth Quarter and Full Year 2023 Financial Results -
February 01, 2024
Ted Love, MD, Joins Gilead Sciences’ Board of Directors
January
-
January 30, 2024
Kite Receives U.S. FDA Approval of Manufacturing Process Change Resulting in Reduced Median Turnaround Time for Yescarta® CAR T-cell Therapy -
January 29, 2024
Gilead and Arcus Announce Amended Collaboration and Equity Investment -
January 23, 2024
Gilead Sciences to Release Fourth Quarter & Full Year 2023 Financial Results on Tuesday, February 6, 2024 -
January 22, 2024
Gilead Provides Update on Phase 3 EVOKE-01 Study
Filter By Year